IDH1 and acute myeloid leukemia: Studies in AML of azacitidine in combination with the BCL2 inhibitor, venetoclax (ClinicalTrials.gov NCT03466294), the mutant IDH inhibitors, enasidenib and ivosidenib (NCT02677922), and the mutant FLT3 inhibitors, gilteritinib (NCT02752035) and quizartinib (NCT01892371), are currently ongoing.